- Trials with a EudraCT protocol (193)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
193 result(s) found for: Pioglitazone.
Displaying page 5 of 10.
EudraCT Number: 2005-000570-52 | Sponsor Protocol Number: 1/2005 | Start Date*: 2006-03-17 |
Sponsor Name:CRC, Medical Department IV, University Erlangen-Nuremberg | ||
Full Title: Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck | ||
Medical condition: essential hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001744-39 | Sponsor Protocol Number: BC20963 | Start Date*: 2008-10-21 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes m... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000486-38 | Sponsor Protocol Number: SYR-322_301 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd., | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subject... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002488-20 | Sponsor Protocol Number: mk 431 prot 052 | Start Date*: 2006-06-15 | |||||||||||
Sponsor Name:MERCK SHARP DOHME | |||||||||||||
Full Title: Studio Multicentrico randomizzato in doppio cieco per valutare la sicurezza e l'efficacia dell'aggiunta di sitagliptin MK 0431 in pazienti affetti da diabete mellito di tipo 2 in trattamento con me... | |||||||||||||
Medical condition: diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005767-34 | Sponsor Protocol Number: NN5401-3593 | Start Date*: 2009-10-07 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing efficacy and safety of NN5401 with insulin glargine, both in combination with oral antidiabetic drugs in subjects with type 2 diabetes | |||||||||||||
Medical condition: type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016051-22 | Sponsor Protocol Number: CL004_140 | Start Date*: 2010-02-09 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus in subjects with insufficient glycemic control on a stable dose of metformin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002672-25 | Sponsor Protocol Number: STR001-201 | Start Date*: 2015-11-18 |
Sponsor Name:Strekin AG | ||
Full Title: A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear ... | ||
Medical condition: Prevention of Hearing Loss after Cochlear Implant Surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006719-20 | Sponsor Protocol Number: 0431-082 | Start Date*: 2009-05-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. | |||||||||||||
Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000854-11 | Sponsor Protocol Number: H80-MC-GWCH | Start Date*: 2008-09-26 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) SK (Completed) ES (Completed) FR (Completed) DE (Completed) IT (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003152-10 | Sponsor Protocol Number: Verges Hors AOI 2007 | Start Date*: 2007-10-10 |
Sponsor Name:CHU DIJON | ||
Full Title: Influence du traitement par glitazones sur les Phospholipases A2 et sur l'effet des Lipoprotéines de haute densité (HDL) sur la réactivité artérielle, au cours du diabète de type 2 | ||
Medical condition: Diabète de type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004455-37 | Sponsor Protocol Number: ATS K024 (D-Pio-114) | Start Date*: 2007-03-05 | |||||||||||
Sponsor Name:Takeda Pharma GmbH | |||||||||||||
Full Title: Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic Dyslipidemia | |||||||||||||
Medical condition: Patients with Type 2 Diabetes mellitus (HbA1c > 6.5% and >/ = 9%) and diabetic dylipidemia inefficiently treated with Metformin monotherapy (maximal individually tolerated dose) will be eligible fo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000152-19 | Sponsor Protocol Number: 1 | Start Date*: 2022-02-24 |
Sponsor Name:Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) | ||
Full Title: Control strategies and pharmacogenetic study for the personalized treatment of fatty liver associated with metabolic dysfunction in patients with prediabetes. | ||
Medical condition: Metabolic Associated Fatty Liver Disease with prediabetes. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002466-38 | Sponsor Protocol Number: CLAF237A2329 / CLAF237A2329E1 | Start Date*: 2004-11-01 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with ... | ||
Medical condition: Diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003876-38 | Sponsor Protocol Number: EDP305-102 | Start Date*: 2020-08-19 | |||||||||||
Sponsor Name:Enanta Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2) | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016154-40 | Sponsor Protocol Number: 1245.19 | Start Date*: 2010-07-16 | |||||||||||
Sponsor Name:Boehringer Ingelheim Ellas AE | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled parallel group efficacy and safety trial of BI 10773 (10 and 25 mg administered orally once daily) over 24 weeks in patients with type 2 diabetes mell... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001873-42 | Sponsor Protocol Number: D1690R00009 | Start Date*: 2015-10-27 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: Pragmatic Randomised 104 Week Multicentre Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study. | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000242-22 | Sponsor Protocol Number: STR001-202 | Start Date*: 2017-06-28 | |||||||||||
Sponsor Name:STREKIN AG | |||||||||||||
Full Title: A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing Loss | |||||||||||||
Medical condition: Sudden Sensorineural Hearing Loss (SSHL) including - idiopathic unilateral Sensorineural Hearing Loss - acute uni- or bilateral acoustic trauma-induced Sensorineural Hearing Loss | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004028-35 | Sponsor Protocol Number: ATS K023 / D-Pio-110 | Start Date*: 2007-02-12 | |||||||||||
Sponsor Name:Takeda Pharma GmbH | |||||||||||||
Full Title: Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk a... | |||||||||||||
Medical condition: Non-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014833-26 | Sponsor Protocol Number: IEO S500/409 | Start Date*: 2010-07-29 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions. An Inter-Consortium Collaborative Study. | |||||||||||||
Medical condition: oral premalignant lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
